-
-
-
-
-
-
-
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
-
-
-
-
-
-
-
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
-
-
-
-
-
-
-
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
-
-
-
-
66,470 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

